Key Financial Figures (FY 2025-26)

  • Revenue from operations and other income: ₹31.20 crore (prev. FY: ₹28.06 crore)
  • Profit before tax: ₹5.39 crore (prev. FY: ₹3.86 crore)
  • Net profit after tax: ₹4.12 crore (prev. FY: ₹2.83 crore)
  • Basic and diluted EPS: ₹5.97 (prev. FY: ₹4.11)
  • Finance costs: ₹1.31 crore
  • Depreciation and amortization: ₹24.13 lakh
  • Current tax expense: ₹1.43 crore
  • Deferred tax asset: ₹16.60 lakh
  • Total paid-up capital: ₹8.71 crore (₹6.90 crore equity + ₹1.81 crore preference)
  • Reserves and surplus: ₹5.54 crore
  • Total borrowings: ₹9.16 crore (₹1.46 crore long-term + ₹7.70 crore short-term)
  • Trade receivables: ₹16.13 crore
  • Inventories: ₹6.21 crore
  • Cash and cash equivalents: ₹59.24 lakh

IPO and Listing Details

  • Successfully completed Initial Public Offering (IPO)
  • 27,00,000 equity shares of face value ₹10 each issued at ₹43 per share (including premium of ₹33 per share)
  • Equity shares listed on BSE SME Platform on May 19, 2026
  • Total issue size: ₹11.61 crore

Annual General Meeting Details

  • 22nd AGM scheduled for Saturday, August 29, 2026 at 4:00 PM
  • Venue: Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025
  • Cut-off date: Saturday, August 22, 2026
  • Book closure: August 23, 2026 to August 29, 2026
  • E-voting period: August 25, 2026 (9:00 AM) to August 28, 2026 (5:00 PM)

AGM Agenda Items

Ordinary Business

1. Adoption of audited financial statements for year ended March 31, 2026

2. Declaration of dividend on preference shares for FY 2025-26 at 12% per annum (aggregating ₹21.68 lakh)

3. Re-appointment of Mr. Prashant Shrikrishna Karkare (DIN: 06572686) as Executive Director

Special Business

4. Approval of existing and new material related party transactions with Activista Healthcare Private Limited

  • FY 2025-26 transactions: ₹113.00 lakh
  • FY 2024-25 transactions: ₹245.88 lakh
  • FY 2023-24 transactions: ₹392.68 lakh

5. Approval of existing and new material related party transactions with Nucleage Pharma Solutions Private Limited

  • FY 2025-26 transactions: ₹555.64 lakh
  • FY 2024-25 transactions: ₹256.23 lakh
  • FY 2023-24 transactions: ₹122.68 lakh

6. Approval of existing and new material related party transactions with Numerius Healthcare Private Limited

  • FY 2025-26 transactions: ₹1.96 lakh
  • FY 2024-25 transactions: ₹304.33 lakh
  • FY 2023-24 transactions: ₹60.75 lakh

7. Borrowing of unsecured loans from directors with option of convertibility into equity shares

  • Overall borrowing limit: ₹200 crore
  • Conversion terms to be determined in accordance with SEBI regulations
  • Shares allotted upon conversion to rank pari passu with existing shares

8. Approval of loans, investments, guarantees or security under Section 185 of Companies Act, 2013

  • Aggregate limit: ₹200 crore
  • To be provided to subsidiaries, associates, joint ventures, or managing/whole-time directors

Corporate Structure and Governance

Board of Directors

1. Mr. Amol Mujumdar - Chairman and Managing Director (DIN: 01910549)

2. Mr. Swapan Khandelwal - Whole-Time Director (DIN: 03486882)

3. Mr. Prashant Karkare - Executive Director (DIN: 06572686)

4. Mr. Avinash Ambulkar - Executive Director (DIN: 06572695)

5. Mr. Prashant Rahate - Non-Executive Director (DIN: 02418548)

6. Mr. Mehul Ranade - Independent Director (DIN: 08949206)

7. Ms. Shraddha Kulkarni - Independent Director (DIN: 10809419)

8. Ms. Renuka Borle - Independent Director (DIN: 10735899)

Key Managerial Personnel

1. Ms. Dipti Sharad Bhusari - Chief Financial Officer

2. Ms. Ruchi Sanket Modi - Company Secretary cum Compliance Officer

Committee Composition

  • Audit Committee: Mr. Mehul Ranade (Chairman), Ms. Shraddha Kulkarni, Ms. Renuka Borle
  • Nomination & Remuneration Committee: Ms. Shraddha Kulkarni (Chairman), Mr. Prashant Rahate, Mr. Mehul Ranade
  • Stakeholders Relationship Committee: Ms. Shraddha Kulkarni (Chairman), Mr. Prashant Rahate, Mr. Amol Mujumdar

Professional Appointments

  • Statutory Auditor: M/s. B Shroff & Co, Chartered Accountants
  • Internal Auditor: M/s. Kunal Dutt & Associates, Chartered Accountants
  • Corporate Consultant: M/s. Avinash Gandhewar & Associates, Practicing Company Secretaries
  • Registrar and Share Transfer Agent: Bigshare Services Private Limited

Business Overview

Goldline Pharmaceutical Limited operates in multiple Indian states (Maharashtra, Chhattisgarh, Madhya Pradesh, Orissa, Tamil Nadu, Rajasthan, Jharkhand, Goa & Bihar) with over 20 years of experience. The company markets pharmaceutical products under five categories:

1. Goldline Pharma: 42 products for Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology

2. Goldline Cardinal: 54 products for Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians

3. Goldline Aayushman: 18 products for Pediatricians, Child Specialists, Neonatologists, and General Practitioners

4. Goldline InLife: 22 injectable products for Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians

5. Goldline Wellness: 10 supportive care products for cancer patients

The company follows an asset-light business model with products manufactured by third-party contract manufacturers based on company specifications.

Dividend Declaration

  • No dividend recommended for equity shareholders
  • Preference dividend recommended at 12% per annum for FY 2025-26, aggregating ₹21.68 lakh
  • Preference dividend of ₹21.68 lakh paid during the year

Capital Structure

Authorized Capital

  • ₹11.00 crore divided into 1,10,00,000 equity shares of ₹10 each
  • ₹2.50 crore divided into 2,50,000 preference shares of ₹100 each

Issued, Subscribed and Paid-up Capital

  • ₹6.90 crore divided into 69,00,000 equity shares of ₹10 each
  • ₹1.81 crore divided into 1,80,700 preference shares of ₹100 each

Shareholding Pattern (Promoters)

  • Mr. Amol Mujumdar: 27,49,988 shares (39.85%)
  • Mr. Swapan Khandelwal: 27,49,988 shares (39.85%)
  • Mr. Sumit Bilgaiyan: 6,75,000 shares (9.78%)

Related Party Transactions

Transaction Values with Related Parties (FY 2025-26)

  • Activista Healthcare Private Limited: ₹113.00 lakh
  • Nucleage Pharma Solutions Private Limited: ₹555.64 lakh
  • Numerius Healthcare Private Limited: ₹1.96 lakh

Outstanding Balances with Related Parties (as of March 31, 2026)

  • Activista Healthcare Private Limited: ₹205.05 lakh
  • Nucleage Pharma Solutions Private Limited: ₹194.88 lakh
  • Numerius Healthcare Private Limited: ₹64.04 lakh

Remuneration Details

Director Remuneration (FY 2025-26)

  • Mr. Amol Mujumdar: ₹60.00 lakh
  • Mr. Swapan Khandelwal: ₹60.00 lakh
  • Mr. Prashant Karkare: ₹11.78 lakh
  • Mr. Avinash Ambulkar: ₹4.48 lakh

Key Managerial Personnel Remuneration (FY 2025-26)

  • Ms. Dipti Bhusari (CFO): ₹4.90 lakh
  • Ms. Ruchi Modi (Company Secretary): ₹2.63 lakh

Employee Information

  • Total permanent employees: 126
  • Median remuneration: ₹3,84,456
  • Increase in median remuneration: 7.46% from previous year's ₹3,57,756

Financial Impact

  • The IPO strengthened the capital base and enhanced market visibility
  • Related party transactions are in ordinary course of business and at arm's length
  • Borrowing proposal of ₹200 crore to provide financial flexibility
  • No material changes affecting financial position except the IPO listing